Ketamine Infusion vs Dexmedetomidine Infusion in Obese Patients Undergoing Bariatric Surgery
Status:
Active, not recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The surgeries that involve treatment of morbid obesity, i.e. bypass procedure and sleeve
gastrectomy, are collectively covered under the term 'bariatric surgery'. The frequency of
bariatric surgery has been increasing worldwide for patients with medically complicated
obesity who have difficulty losing weight by other methods
The growth of bariatric surgery is accompanied with development of anesthetic techniques to
maintain patient safety and improve outcome. Treatment with narcotics in obese patients has
dual effect. Increased use of narcotics are associated with multiple complications including
Postoperative Nausea and Vomiting (PONV) , respiratory depression and elevated risk of
Obstructive Sleep Apnea (OSA) complications . On the other hand, the reduction in opioid use
may result in acute post-operative pain that may limit post-surgery rehabilitation.
Therefore, we need to minimize opioid use and employ some other drugs which, besides having
analgesia, has an opioid-sparing effect also.
Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has analgesic properties in
sub-anesthetic doses. When used in low dose (0.3 to 0.5 mg/kg) by ideal body weight, it is an
analgesic, anti-hyperalgesic, and prevents development of opioid tolerance.
Dexmedetomidine is selective α2-Adrenoceptor agonist that has been used as an adjuvant to
anesthetic agents in perioperative period for several adventitious profile as well as
tolerated side effects . While dexmedetomidine is emerging as a beneficial adjunct to the
analgesic regimen in the perioperative period, its utilization is not routinely widespread .